Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide
Economic impact of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide on families
5 evidence topics · 5 sources
Caregiver time, finances, and employment
“Caregivers often spouses or partners, provide practical, financial, and emotional support, averaging 11 hours/week of providing care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the majority of caregivers (58% to 60%), providing care affects their finances (60%), sleep (60%), energy level (59%), mood/mental health (58%), and overall day-to-day life (58%). More than half of caregivers (53%) report an impact on their ability to work.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 79% of caregivers who worked outside the home before their patient’s mCRPC diagnosis, 40% reduced their working hours, 13% stopped working completely, 3% retired as planned, and 43% made other changes; only 15% continued working normally post-diagnosis (Supplementary Table S1). Among those who reduced work hours, 64% reduced their hours by half or more.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of high financial toxicity and coping behaviors
“Overall, 281 patients met inclusion criteria of which 79 reported high financial toxicity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with high financial toxicity were more likely to decrease spending on basic goods (35% vs 2.5%, P < .001) and leisure activities (59% vs 15%, P > .001), as well as use savings (62% vs 17%, P < .001) to pay for their treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Indirect costs and the role of informal caregivers
“Qualitative descriptions were congruent with quantitative items assessing indirect costs of treatment, with many patients describing alterations to work, early retirement, and caregiver lifestyle changes (Quotes 1.2.2, 1.2.3, 1.2.5). Additional indirect costs not evaluated by the quantitative assessment included the opportunity cost of time spent navigating insurance coverage, as well as costs of travel to treatment sites, including gas, commute time, hotel expenses, and even relocating to be closer to care (Quotes 1.2.2, 1.2.4, 1.2.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, how treatment costs impacted the lives of patients’ loved ones was a strong contributor to the degree of financial stress that they experienced (Quotes 3.3.3, 3.3.4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket payments for oral androgen receptor pathway inhibitors under Medicare Part D
“There were 4,153 patients who filled abiraterone or enzalutamide through Medicare Part D in 228 hospital-referral regions. Mean adherence was 75%. Median monthly out-of-pocket payment for abiraterone and enzalutamide was $706 (range $0 to $3,505).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket payments by first-line agent: employer-sponsored insurance
“OOP payments were lower than gross drug payments; mean 6-month OOP payments were highest for cabazitaxel ($1,044 USD) and lowest for docetaxel ($296 USD). There was a wide distribution of OOP payments within drug types.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote